Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors

Davis González, María Rocío; Ballester, María Pilar; Romero-González, Eva; Sánchez-Pardo, Ana María; Marti-Aguado, David; Tosca, Joan; Suria, Carles; Antón Ausejo, Rosario; Pascual Moreno, Isabel; Planelles Silvestre, María Dolores.
Gastroenterol. hepatol. (Ed. impr.) ; 46(9): 671-681, nov. 2023. ilus, tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-226944

Documentos relacionados

  1. Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors.
  2. Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis.
  3. Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis.
  4. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric-Onset IBD Cohort.
  5. The Effect of Biologics on Postoperative Complications in Children With Inflammatory Bowel Disease and Bowel Resection.
  6. Intralesional biologics for inflammatory dermatoses: A systematic review.
  7. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
  8. Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease.
  9. Retrospective analysis of patients with psoriasis receiving biological therapy: Real-life data.
  10. Fluctuations in serum levels of adalimumab and infliximab in patients on stable treatment for psoriasis.